Editorial Board Disclosure Policy
(Last updated May 2023)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Dr Charlotte Bevan
Dr Bevan has received studentships in partnership with Carrick Therapeutics.
Dr Bevan has received studentships in partnership with Carrick Therapeutics.
Dr Elizabeth Caldon
Dr Caldon had a since terminated contract research agreement in 2020 with Constellation Pharmaceuticals plus provision of drugs, and also received honoraria from Eli Lilly.
Dr Caldon had a since terminated contract research agreement in 2020 with Constellation Pharmaceuticals plus provision of drugs, and also received honoraria from Eli Lilly.
Dr Ruth Casey
Dr Casey has received honoraria from Novartis for an educational session in 2022.
Dr Casey has received honoraria from Novartis for an educational session in 2022.
Dr Ben Challis
Dr Challis is an employee of AstraZenaca and holds AstraZeneca stocks and share options.
Dr Challis is an employee of AstraZenaca and holds AstraZeneca stocks and share options.
Dr Scott Dehm
Dr Dehm consults for Oncternal Therapeutics and Bristol-Myers Squibb.
Dr Dehm consults for Oncternal Therapeutics and Bristol-Myers Squibb.
Professor Tobias Else
Professor Else has received grants from the NIH and Department of Defense, and acts on the Advisory board of HRA Pharma, Merck and Lantheus.
Professor Else has received grants from the NIH and Department of Defense, and acts on the Advisory board of HRA Pharma, Merck and Lantheus.
Professor Simona Glasberg
Professor Glasberg has received research grants from Medison and Novartis, and consultancy for Serb, Camurus, Triple A, Debiopharm and ITM. She has a patent pending, Hadasit Ref: 996-01 - US Patent Application No. 63/343,129 for "Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms". She is a Senior Editor for Journal of Neuroendocrinology; and Chair of the ENETS Carcinoid Heart Disease Task Force, Co-Chair of ESE Rare Disease Committee, Member of ESE Executive Committee (2019-2023), Co-Leader of the Working Group for Research Roadmap in Neuroendocrine Tumors of ESE, Member of the Israel Endocrine Society Executive Committee and a Member of ESMO Faculty.
Professor Glasberg has received research grants from Medison and Novartis, and consultancy for Serb, Camurus, Triple A, Debiopharm and ITM. She has a patent pending, Hadasit Ref: 996-01 - US Patent Application No. 63/343,129 for "Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms". She is a Senior Editor for Journal of Neuroendocrinology; and Chair of the ENETS Carcinoid Heart Disease Task Force, Co-Chair of ESE Rare Disease Committee, Member of ESE Executive Committee (2019-2023), Co-Leader of the Working Group for Research Roadmap in Neuroendocrine Tumors of ESE, Member of the Israel Endocrine Society Executive Committee and a Member of ESMO Faculty.
Professor Hannelore Heemers
Professor Heemers has received grant support from VeloSano, VeloSano8 pilot research award, the Department of Cancer Biology/Cleveland Clinic Cancer Biology MultiPI Project Development Award and the NIH/NCI. They act as a paid reviewer on the NCI study section MCT2/MCTA, reviewer and chair on review panels for Congressionally Directed Medical Research Programs and the Prostate Cancer Research Program. Dr Heemers is also the inventor on US patent application PCT/US2022/02349.
Professor Heemers has received grant support from VeloSano, VeloSano8 pilot research award, the Department of Cancer Biology/Cleveland Clinic Cancer Biology MultiPI Project Development Award and the NIH/NCI. They act as a paid reviewer on the NCI study section MCT2/MCTA, reviewer and chair on review panels for Congressionally Directed Medical Research Programs and the Prostate Cancer Research Program. Dr Heemers is also the inventor on US patent application PCT/US2022/02349.
Professor Johannes Hofland
Professor Hofland Hofland has received an advisory board fee from Novartis and Ipsen, and a speaker fee from Ipsen.
Professor Hofland Hofland has received an advisory board fee from Novartis and Ipsen, and a speaker fee from Ipsen.
Dr Lawrence Kirschner
Dr Kirschner has received research support from the NIH. He also serves as site PI for industry sponsored clinical trials (which may include support for resources or staff, as well as travel to investigator meetings) for the following companies: Corcept, Crinetics, CinCOR, Sparrow, Spruce and Adrenas. He has also received payment from consulting and serving on the speaker’s bureau for Corcept and holds patents on identification of PRKAR1A as the cause of Carney Complex.
Dr Kirschner has received research support from the NIH. He also serves as site PI for industry sponsored clinical trials (which may include support for resources or staff, as well as travel to investigator meetings) for the following companies: Corcept, Crinetics, CinCOR, Sparrow, Spruce and Adrenas. He has also received payment from consulting and serving on the speaker’s bureau for Corcept and holds patents on identification of PRKAR1A as the cause of Carney Complex.
Professor André Lacroix
Professor Lacroix has received Clinical and Research Fellows salary support to his institution from Pfizer, Recordati, Ipsen and Corcept.
Professor Lacroix has received Clinical and Research Fellows salary support to his institution from Pfizer, Recordati, Ipsen and Corcept.
Dr Ann McCormack
Dr McCormack has received honoraria for giving lectures from Pfizer, IPSEN and Novo Nordisk.
Dr McCormack has received honoraria for giving lectures from Pfizer, IPSEN and Novo Nordisk.
Dr Cristina Ronchi
Dr Ronchi has received research grants from HRA Pharma.
Dr Ronchi has received research grants from HRA Pharma.
Professor Shigehira Saji
Professor Shigehira Saji consults for Astra Zeneca, Chugai, Eli Lilly, Kyowa Kirin, MSD, Ono and Pfizer. They also carry out contracted research for Astra Zeneca, Chugai, Daiichi Sankyo, MSD and Taiho, and have received payment for lecturing at Astra Zeneca, Chugai, Eli Lilly, Kyowa Kirin, MSD, Ono and Pfizer.
Professor Shigehira Saji consults for Astra Zeneca, Chugai, Eli Lilly, Kyowa Kirin, MSD, Ono and Pfizer. They also carry out contracted research for Astra Zeneca, Chugai, Daiichi Sankyo, MSD and Taiho, and have received payment for lecturing at Astra Zeneca, Chugai, Eli Lilly, Kyowa Kirin, MSD, Ono and Pfizer.
Dr Renea Taylor
Dr Taylor conducts research in collaboration with AstraZeneca, who provide funding for research studies and supply of drug for laboratory research.
Dr Taylor conducts research in collaboration with AstraZeneca, who provide funding for research studies and supply of drug for laboratory research.
Professor Marily Theodoropoulou
Professor Theodoropoulou Therodoropoloulou has received grants from the German Research Foundation (DFG) and Crinetics Pharmaceuticals Inc.
Professor Theodoropoulou Therodoropoloulou has received grants from the German Research Foundation (DFG) and Crinetics Pharmaceuticals Inc.
Dr Maria Chiara Zatelli
Dr Zatelli has received grants from the Italian Ministry of Research and consults for Sandoz, Lilly and Sanofi Aventis.
Dr Zatelli has received grants from the Italian Ministry of Research and consults for Sandoz, Lilly and Sanofi Aventis.
Dr Nicole Unger
Dr Unger is on the advisory board for Merck Serono. She also received speaker fees from Ipsen, Recordati Rare Diseases, Merck Serono and HRA Pharma.
Dr Unger is on the advisory board for Merck Serono. She also received speaker fees from Ipsen, Recordati Rare Diseases, Merck Serono and HRA Pharma.
The following editor reported no competing interests:
- Dr Kate Lines
- Dr Yasuhiro Miki
- Dr Patrick Petrossians
- Dr Claudia Pelizas
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).
